BI/Lilly's Jentadueto wins EU approval
This article was originally published in Scrip
Executive Summary
The European Commission has approved Boehringer Ingelheim/Lilly’s antidiabetic Jentadueto, which combines the DDP-4 inhibitor linagliptin (Trajenta/Tradjenta) and metformin in a single pill. It is approved for use along with diet and exercise to improve glycaemic control in adults with type 2 diabetes who are inadequately controlled on their maximal tolerated dose of metformin alone, or for those already being treated with linagliptin and metformin with or without an insulin secretagogue such as sulphonylurea.